Neurodegenerative DisordersJOCONDENCT05394974
Joint Consultation Between a Neurologist and a Clinical Psychologist
An observational study of Neurodegenerative Disorders, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Joint consultations appeared a few years ago in routine medical practice, but they are still not widely used and rarely evaluated. The primary purpose of the study is to evaluate the impact for the patient of the presence of a clinical psychologist during the joint consultation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neurodegenerative Disorders
- How many people
- 200 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jun 2021to 1 Jun 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult patient with a neurodegenerative and/or neurogenetic disease
Who may be able to join
- patient with a neurodegenerative and/or neurogenetic disease
- adult patient
Who cannot join
- dementia
- age <18 years
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Service de Neurologie - CHU de Strasbourg - France
Strasbourg, 67091
Mathieu ANHEIM, MD, PhD, +33388128535, mathieu.anheim@chru-strasbourg.fr
Mathieu ANHEIM, MD, PhD
About this study
Official title: Evaluation of a Joint Consultation Between a Neurologist and a Clinical Psychologist, Dedicated to Neurodegenerative and/or Neurogenetic Disorders
Joint consultations appeared a few years ago in routine medical practice, but they are still not widely used and rarely evaluated.
The primary purpose of the study is to evaluate the impact for the patient of the presence of a clinical psychologist during the joint consultation.
The secondary purpose is to evaluate the impact for the patient and for the neurologist of the presence of a clinical psychologist during the joint consultation
- Conditions
- Neurodegenerative Disorders
- Keywords
- Joint neurologist, psychologist consultation, neurodegenerative and/or neurogenetic disease
- Medical subject headings
- Neurodegenerative Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient satisfaction after the consultation assessed by 3 questions on a Likert scale
5-point Likert scale from which to select a response :
- Very satisfied.
- Moderately satisfied.
- Neither satisfied nor dissatisfied.
- Moderately dissatisfied.
- Very dissatisfied.
Measured: After consultation et 1 to 3 months later
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2022
- Study start1 Jun 2021
- Primary completion1 Jun 2023 (estimated)
- Study completion1 Jun 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurodegenerative DisordersStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mathieu ANHEIM, MD, PhD, Principal investigator, Service de Neurologie - CHU de Strasbourg - France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05394974
- Sponsor's protocol ID
- JOCONDE
- Acronym
- JOCONDE
- Status last verified
- May 2022
- First submitted
- 23 May 2022
- Last updated
- 13 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Joint Consultation Between a Neurologist and a Clinical Psychologist, Dedicated to Neurodegenerative and/or Neurogenetic Disorders
- ClinicalTrials.gov ID
- NCT05394974
- Acronym / sponsor ID
- JOCONDE / JOCONDE
- Conditions
- Neurodegenerative Disorders
- Keywords
- Joint neurologist, psychologist consultation, neurodegenerative and/or neurogenetic disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 1 Jun 2023 (estimated)
- Study completion
- 1 Jun 2023 (estimated)
- First posted
- 27 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Joint consultations appeared a few years ago in routine medical practice, but they are still not widely used and rarely evaluated.
The primary purpose of the study is to evaluate the impact for the patient of the presence of a clinical psychologist during the joint consultation.
The secondary purpose is to evaluate the impact for the patient and for the neurologist of the presence of a clinical psychologist during the joint consultation
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patient with a neurodegenerative and/or neurogenetic disease
Key inclusion criteria (2 listed)
- patient with a neurodegenerative and/or neurogenetic disease
- adult patient
Key exclusion criteria (2 listed)
- dementia
- age <18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patient satisfaction after the consultation assessed by 3 questions on a Likert scale
Time frame: After consultation et 1 to 3 months later
5-point Likert scale from which to select a response : 1. Very satisfied. 2. Moderately satisfied. 3. Neither satisfied nor dissatisfied. 4. Moderately dissatisfied. 5. Very dissatisfied.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jun 2022.
Related trials for Neurodegenerative Disorders
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
Active, not recruitingPhase 4
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Muscular Atrophy, Spinal
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mathieu ANHEIM, MD, PhD principal investigator
Service de Neurologie - CHU de Strasbourg - France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurodegenerative Disorders, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mathieu ANHEIM, MD, PhD (+33 3 88 12 85 35, mathieu.anheim@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient satisfaction after the consultation assessed by 3 questions on a Likert scale (time frame: After consultation et 1 to 3 months later). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jun 2022.